Buscar
Mostrando documentos 1-2 de 2
Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebocontrolled, phase 2 trial
Background This is the first randomised controlled trial for assessment of the immunogenicity and safety of a
candidate non-replicating adenovirus type-5 (Ad5)-vectored COVID-19 vaccine, aiming to determine an appropriate
dose ...
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial
Background A vaccine to protect against COVID-19 is urgently needed. We aimed to assess the safety, tolerability, and
immunogenicity of a recombinant adenovirus type-5 (Ad5) vectored COVID-19 vaccine expressing the ...